Alps Advisors Inc. cut its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 33.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,265 shares of the biopharmaceutical company’s stock after selling 1,607 shares during the period. Alps Advisors Inc.’s holdings in Alexion Pharmaceuticals were worth $458,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Fiduciary Trust Co. acquired a new stake in shares of Alexion Pharmaceuticals during the second quarter worth $111,000. Huntington National Bank lifted its stake in shares of Alexion Pharmaceuticals by 1,084.6% during the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after buying an additional 987 shares during the period. Dupont Capital Management Corp acquired a new stake in shares of Alexion Pharmaceuticals during the third quarter worth $156,000. BT Investment Management Ltd acquired a new stake in shares of Alexion Pharmaceuticals during the third quarter worth $165,000. Finally, Penserra Capital Management LLC lifted its stake in shares of Alexion Pharmaceuticals by 13.0% during the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after buying an additional 144 shares during the period. Hedge funds and other institutional investors own 95.80% of the company’s stock.

ALXN has been the subject of several recent research reports. SunTrust Banks, Inc. reissued a “buy” rating and set a $180.00 target price (up previously from $170.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Deutsche Bank AG reissued a “buy” rating and set a $158.00 target price (up previously from $153.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. BMO Capital Markets reissued an “outperform” rating and set a $173.00 target price (up previously from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. BidaskClub raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Evercore ISI initiated coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, August 16th. They set an “in-line” rating and a $137.00 target price for the company. Six investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $154.01.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) opened at $108.49 on Tuesday. The company has a quick ratio of 2.51, a current ratio of 2.96 and a debt-to-equity ratio of 0.35. The firm has a market cap of $24,769.42, a PE ratio of 22.67, a price-to-earnings-growth ratio of 1.21 and a beta of 1.22. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, beating the consensus estimate of $1.32 by $0.12. The company had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. Alexion Pharmaceuticals’s revenue was up 7.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.23 EPS. equities research analysts predict that Alexion Pharmaceuticals, Inc. will post 4.81 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This article was first reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2017/11/21/alps-advisors-inc-sells-1607-shares-of-alexion-pharmaceuticals-inc-alxn.html.

In other news, EVP Julie O’neill sold 4,375 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.44, for a total value of $636,300.00. Following the sale, the executive vice president now directly owns 26,092 shares of the company’s stock, valued at approximately $3,794,820.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ann M. Veneman sold 835 shares of the business’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $145.81, for a total transaction of $121,751.35. Following the completion of the sale, the director now directly owns 5,480 shares in the company, valued at $799,038.80. The disclosure for this sale can be found here. Insiders sold a total of 16,490 shares of company stock worth $2,337,251 over the last quarter. 4.35% of the stock is currently owned by company insiders.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.